@genetic-counselor
Genetic Counselor
Forum Replies Created
-
Posts
-
When FISH is used for the exact purpose, it is designed for, checking one known, well-characterized region, it is highly accurate. Laboratory standards set by the ACMG require that each probe be validated for at least 95% sensitivity before it is used clinically, and testing of relatives for an already-confirmed familial change typically approaches 100% reliability, since the laboratory knows exactly what pattern it is looking for and has a known comparison available.
The accuracy of this test is tightly bound to its focus, however, and this is the single most important limitation for families to understand. A normal result only rules out the one specific change the probe was designed to detect; it says nothing about the rest of that person’s genetic material. As an example, in 22q11.2 deletion syndrome, the standard fluorescence in situ hybridization probes target a defined stretch of the chromosome, and they can miss an estimated 5-15% of cases where the deletion is unusually positioned outside that exact stretch, even though the person has genuinely inherited a clinically significant version of the same condition. For this reason, when a family’s situation is not already narrowed down to one clear possibility, chromosomal microarray or sequencing-based testing, which survey much more of the genome at once, are generally recommended as the more complete first test, with fluorescence in situ hybridization reserved for situations where speed or an already-known target makes it the better tool.
This test also has a resolution limit; it cannot detect a change within a single gene, such as one altered letter of the genetic code, and it can miss a genetic change that is present in only a small proportion of a person’s cells, a situation called low-level mosaicism, if too few cells are examined. Because interphase testing on non-dividing cells is what makes rapid results possible, results from this approach are also generally treated as preliminary in pregnancy, with a complete chromosome analysis performed afterward to confirm the finding and check for anything the targeted test could not see. As with any genetic test, a geneticist or genetic counsellor reviewing the specific probes used and what they can and cannot rule out is an essential part of understanding what a result truly means.
FISH is used across several distinct clinical situations, each sharing the same underlying logic: a specific genetic question already needs answering quickly or with confirmation.
• A pregnancy where a faster answer is needed. When an ultrasound finding, a screening test, or another concern raises the possibility of a common chromosome condition, such as an extra or missing copy of chromosome 13, 18, 21, X, or Y, this test can typically return a preliminary result within one to two days from a sample obtained through chorionic villus sampling or amniocentesis, well before a full chromosome analysis is complete. Because it only checks a handful of chromosomes, a normal result here is always followed by the complete analysis before major decisions are made.
• A child or adult whose features point to a specific microdeletion or microduplication syndrome. Some genetic conditions, such as 22q11.2 deletion syndrome, produce a recognizable combination of physical, heart, immune, and developmental features that lets a geneticist target one chromosome region directly, rather than scanning the whole genome first.
• A relative of someone with an already-identified chromosome change. Once a specific deletion, duplication, or rearrangement has been confirmed in one family member, this test can check parents, siblings, or other relatives for that exact same change quickly and at lower cost than repeating a full genome-wide test, which matters for understanding whether a change was inherited or arose newly, and for counselling about future pregnancies.
• Confirming a balanced chromosome rearrangement in a parent. When a couple has experienced recurrent pregnancy loss or a previous child with an unbalanced chromosome condition, this test can help characterize a parent’s rearrangement in detail once it has already been identified through a karyotype.
• Cancer diagnosis, prognosis, and treatment planning. Many cancers, particularly blood cancers such as leukemia and lymphoma, and certain solid tumors, are driven by a specific, well-characterized genetic change, such as two genes fusing together or extra copies of a particular gene. Testing tumor or bone marrow cells for these specific changes helps confirm a diagnosis, estimate prognosis, and, for some cancers, determine whether a targeted medication is likely to work.
Across all these situations, this test is chosen because the clinical picture has already narrowed the question down to one, or a small handful, of known possibilities, not because it is the best tool for an open-ended genetic search.
Every cell in the body carries its DNA tightly organized into 46 chromosomes. A FISH probe is built from a strand of DNA that is complementary to one specific stretch of one chromosome, meaning its chemical structure fits that target the way a key fits a lock, and nowhere else in the genome. The probe carries a fluorescent dye attached to it. When the probe is mixed with a person’s cells that have been fixed onto a glass slide, it seeks out and binds tightly to its one matching target and nothing else, a process called hybridization. Under a fluorescence microscope, each bound probe appears as a single glowing dot. A typical cell has two copies of every chromosome, one from each parent, so a healthy result usually shows two dots, one for each copy. One dot instead of two suggests a piece of that region is missing; three or more dots suggest an extra copy; and a dot appearing in an unexpected position on a different chromosome suggests the region has been relocated through a rearrangement.
This test can be performed on cells caught mid-division, when chromosomes are bundled into their familiar compact shape, or on resting cells between divisions, where the DNA is more loosely spread through the nucleus. The second approach, called interphase testing, is what allows many FISH results to be ready in as little as one to two days, since it skips the several days some other tests need to grow living cells into active division.
The key difference from other chromosome tests is focus versus breadth. A karyotype photographs and sorts all 46 chromosomes under a microscope, catching large rearrangements and missing or extra whole chromosomes, but only down to a resolution of roughly five to ten million building blocks of DNA. A chromosomal microarray scans the entire genome at once for missing or duplicated material, at a much finer resolution, but cannot see a rearrangement where material has simply changed position without any being gained or lost, and does not deliver same-day results. Genome or exome sequencing reads the genetic code letter by letter, catching single-gene changes neither of the other tests can see, but is a slower, broader process not typically chosen when a fast, specific answer is needed. FISH sits apart from all three: it is fast and highly reliable for the one region it is aimed at, but it tells a family nothing about the rest of the genome, since the laboratory must already know, in advance, exactly what to look for.
Fluorescence in situ hybridization is a laboratory test that looks for one specific, already-suspected genetic change, rather than scanning the whole genome for anything unusual. The technique works by using a short, custom-made piece of DNA, called a probe, that has been chemically labelled with a fluorescent tag. This probe is designed to match, and stick to, one exact region of one chromosome. When the probe is applied to a person’s cells on a laboratory slide, it binds only to its matching target, and a scientist then looks at the cells under a fluorescence microscope. If the expected region is present in the normal number of copies, the probe lights up in the expected pattern. If a piece of that region is missing, duplicated, or has moved to an unexpected location, the fluorescent pattern changes in a specific, recognizable way, revealing the imbalance.
Because this test is targeted rather than exploratory, a doctor recommends it when there is already a clear, focused question to answer, not as a general first search for an unknown genetic cause. This comes up in a few common situations. A clinical picture may already point strongly toward one specific chromosome region, such as a recognizable pattern of physical features and heart or immune differences associated with a well-known microdeletion syndrome. A family member may already have a confirmed genetic change, and other relatives need to be checked for the same one. A pregnancy may need a same-day or next-day answer about a possible common chromosome condition, faster than other tests can provide. Or a cancer diagnosis may need to be confirmed or refined by looking for a specific genetic change known to drive that particular tumor type and to guide treatment choice.
In every one of these situations, fluorescence in situ hybridization answers one focused question quickly and reliably, using cells that do not need to be grown in the laboratory for days beforehand the way some other chromosome tests do. It is best understood as a precise, confirmatory tool aimed at a known target, working alongside broader tests such as chromosomal microarray and genome sequencing rather than replacing them, as later sections explain in more detail.
The long-term outlook for Alport syndrome varies enormously and depends on three things: which gene is involved, the inheritance pattern, and, within X-linked Alport syndrome specifically, the exact type of variant a person carries. As a general pattern, males with X-linked Alport syndrome caused by a variant that stops the protein from being made at all tend to reach kidney failure earliest, often by their teens or twenties, while those with a variant that only subtly changes the protein tend to progress more slowly, often not reaching kidney failure until their forties. Individuals with autosomal recessive Alport syndrome tend to have a course similar to severely affected males, regardless of their sex, while those with autosomal dominant Alport syndrome and most female carriers of X-linked Alport syndrome tend to have a much slower course, sometimes never reaching kidney failure at all. Because of this wide range, genetic testing that identifies the specific gene and variant is valuable not only for confirming the diagnosis but for giving a family a realistic sense of what to expect and when treatment should begin.
Lifelong, regular follow-up is recommended across all three affected organ systems, with the exact schedule adjusted to how significantly each person is affected:
• Kidneys. Urine testing for blood and protein, blood pressure measurement, and blood tests of kidney function are recommended every six months to one year for individuals with a confirmed diagnosis, and roughly every one to two years for carriers who show only isolated microscopic blood in the urine with no protein.
• Hearing. A hearing test, called an audiogram, is recommended yearly through childhood and adolescence for males with X-linked Alport syndrome and for individuals with autosomal recessive Alport syndrome, then roughly every three years in adulthood; carriers are generally tested only if they notice hearing changes themselves.
• Eyes. An eye examination is recommended at the time of diagnosis, with periodic follow-up thereafter for those with X-linked or autosomal recessive Alport syndrome; carrier relatives rarely need repeat eye examinations unless a problem is found at the first one.
• Kidney transplant recipients are monitored more closely, including regular blood testing for anti-glomerular basement membrane antibodies during the first year after transplant, when the rare rejection complication described above is most likely to appear.Because relatives who carry a single altered gene copy can still show slow, silent kidney changes over decades, current guidance also recommends caution before such a relative donates a kidney to a family member, and this is a topic worth raising directly with the kidney transplant team when it becomes relevant.
There is currently no cure for Alport syndrome, since the underlying gene change cannot be corrected, but treatment that starts early has been shown to meaningfully delay kidney failure, which is why timing matters as much as the treatment itself.
• Medications that block a hormone system called the renin-angiotensin system, most often angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, are the cornerstone of treatment. Current guidance recommends starting these medications as soon as persistent microscopic blood in the urine is confirmed, generally from around two years of age, in sons and daughters with autosomal recessive Alport syndrome and in males with X-linked Alport syndrome, since these groups have a well-established risk of progressing to kidney failure. For daughters and other individuals who carry a single altered copy of the gene and have no protein in the urine, most specialists recommend watching closely rather than starting medication immediately, then beginning treatment promptly once protein appears in the urine.
• Medications from a newer class called SGLT2 inhibitors are increasingly added for adults who already have both protein in the urine and reduced kidney function, used together with, not instead of, the medications above.
• Blood pressure control is monitored closely at every visit, since elevated blood pressure accelerates kidney scarring in Alport syndrome just as it does in other kidney conditions.
• Hearing aids or cochlear implants address hearing loss once it develops; regular hearing evaluation allows these to be introduced at the right time.
• Surgery to remove the lens may be recommended if anterior lenticonus significantly blurs vision, and modern lens replacement techniques generally give good results.
• Dialysis and kidney transplantation become necessary if kidney failure develops despite treatment. Transplantation generally works very well in Alport syndrome, though a small number of recipients, mainly males with X-linked Alport syndrome who had no working collagen network of their own, develop a rare complication in the new kidney called anti-glomerular basement membrane nephritis, in which the immune system reacts against the new, unfamiliar collagen network. Because of this, transplant recipients are monitored closely for this specific antibody, particularly during the first year after transplant.
Care is generally best coordinated by a kidney specialist working alongside a clinical geneticist, an audiologist for hearing, and an eye specialist, so that all three organ systems are followed together rather than separately.Yes, Alport syndrome is inherited, and the pattern of risk in a family depends on which of the three genes carries the pathogenic variant.
X-linked Alport syndrome, caused by changes in COL4A5, follows the same logic as other conditions carried on the X chromosome. A father with X-linked Alport syndrome passes his altered X chromosome to every one of his daughters, who become carriers, and to none of his sons, since sons receive his Y chromosome instead. A mother who carries an altered COL4A5 gene has, with each pregnancy, a 1-in-2 chance of passing it to a child of either sex. Sons who inherit it will develop the condition, usually more severely and consistently than daughters, because they have no second, working copy of the gene to compensate. Daughters who inherit it are often described as carriers, but this term can be misleading: because of a natural process in every female cell called X-inactivation, in which one of the two X chromosomes is randomly switched off, the proportion of cells relying on the working versus the altered copy varies from person to person. As a result, affected daughters can range from having no symptoms at all to developing kidney failure themselves, and the family history alone cannot predict where an individual daughter will fall on that range.
Autosomal recessive Alport syndrome, caused by changes in both copies of COL4A3 or COL4A4, requires that a child inherit one altered copy from each parent, who are usually unaffected carriers themselves. When both parents are carriers, each future pregnancy carries a 1-in-4 chance of an affected child, a 1-in-2 chance of an unaffected carrier child, and a 1-in-4 chance of a child with two working copies. This form affects sons and daughters equally.
Autosomal dominant Alport syndrome, caused by a single altered copy of COL4A3 or COL4A4, means an affected person has, with each pregnancy, a 1-in-2 chance of passing on the condition to a child of either sex, generally with a milder course than the other forms.
Because the risk calculation depends entirely on which gene and which inheritance pattern applies, genetic counseling and testing of the specific variant found in the family are strongly recommended before making decisions about future pregnancies or testing other relatives, including apparently healthy ones.
Alport syndrome mainly affects three organs – the kidneys, the ears, and the eyes – though not everyone develops problems in all three, and the pattern depends heavily on which gene is involved and how it is inherited.
• Kidneys. The earliest and most consistent sign is blood in the urine that is too small in amount to see with the naked eye, called microscopic hematuria, often found first on a routine urine test. Over time, protein can also appear in the urine, a sign called proteinuria, which usually signals that scarring is progressing. Without treatment, kidney function can decline steadily, eventually reaching kidney failure, also called end-stage kidney disease, at an age that varies widely depending on the specific gene and variant involved.
• Hearing. Many individuals develop a gradual, permanent hearing loss that originates in the inner ear, called sensorineural hearing loss. It typically begins with high-pitched sounds in later childhood or the teenage years and slowly progresses, and it does not respond to medication, though hearing aids and other devices help significantly.
• Eyes. Some individuals develop a cone-shaped bulging of the lens called anterior lenticonus, which can blur vision and is considered a strong clue toward the diagnosis when present. Others develop small pale or yellow specks scattered around the central part of the retina, called dot-and-fleck retinopathy, which usually does not affect vision at all. A rarer finding involves changes to the clear front surface of the eye, the cornea.Doctors typically suspect Alport syndrome when persistent microscopic blood in the urine is found together with a family history of kidney disease, hearing loss at a young age, or the characteristic eye findings. Confirming the diagnosis today relies mainly on genetic testing that reads all three relevant genes at once, since this can identify the exact variant, clarify the inheritance pattern for the family, and often avoid the need for more invasive testing. When genetic testing is inconclusive, a kidney biopsy can support the diagnosis: a small tissue sample is examined under a specialized microscope, and specific staining techniques can show whether the normal collagen network is missing from the basement membrane.
Alport syndrome is a genetic condition that damages the tiny filtering units inside the kidneys over time, and it often affects hearing and vision as well. It happens because of changes, called pathogenic variants, in one of three genes – COL4A3, COL4A4, or COL4A5 – that carry the instructions for building type IV collagen, a protein that forms part of the scaffolding found in thin sheets of tissue called basement membranes. These basement membranes sit underneath the filtering units of the kidney, inside the inner ear, and within the lens and retina of the eye, which is why a single gene change can affect all three organs at once even though they seem unrelated.
In a healthy kidney filter, the basement membrane relies on a specific network built from three collagen chains working together – the very chains that COL4A3, COL4A4, and COL4A5 provide instructions for. When one of these genes is altered, that network cannot form correctly. The basement membrane becomes abnormally thin in some areas and abnormally thick, split, or layered in others. Over years, this structural weakness lets red blood cells and, eventually, protein leak into the urine, and it triggers ongoing scarring that gradually reduces how well the kidneys filter blood.
Which gene is involved shapes both how Alport syndrome is passed down in a family and how severe it tends to be:
• COL4A5, located on the X chromosome, is changed in around 4 out of every 5 families with Alport syndrome. This form is called X-linked Alport syndrome.
• COL4A3 and COL4A4, located on chromosome 2, together account for most of the remaining families. When a person inherits an altered copy from both parents, it is called autosomal recessive Alport syndrome; when a single altered copy causes a milder, later-onset form on its own, it is called autosomal dominant Alport syndrome.
• Digenic Alport syndrome, in which a person carries pathogenic variants in two of the three genes at once, is rare and tends to cause disease of a severity in between the other forms.
Because the underlying problem is structural – a scaffolding protein that is not built correctly – rather than a toxin or infection, Alport syndrome cannot be caught from another person and nothing the family did caused it.The single most important step is the same one that professional genetics organizations consistently recommend: do not make any medical decision, and try not to assume the worst, based on a direct-to-consumer result alone. Bring the report to a doctor or, ideally, a genetic counselor or clinical geneticist, along with as much detail about your family’s medical history as you can gather. A genetics professional will look at three things together: whether the finding is the kind of variant that is well established as disease-causing, whether it fits with your personal and family history, and whether it needs to be confirmed through accredited, clinical-grade testing before anything else is decided. As the false-positive research described earlier shows, a meaningful proportion of concerning results, especially those generated through third-party raw-data interpretation rather than a company’s own core report, do not hold up once retested properly, so confirmation is not an optional extra step, it is a necessary one.
If the finding is confirmed as genuine, a genetic counselor can then explain what it does and does not mean for your future health, what it might mean for blood relatives such as siblings, parents, or children, and what medical follow-up, screening, or further testing makes sense given the complete clinical picture rather than the genetic result in isolation. This is also the point at which a genetic counselor can identify whether a broader, more appropriate clinical test exists, for example a full gene panel rather than the handful of variants a consumer kit checked, if your family history suggests the direct-to-consumer test may not have looked far enough.
Genetic counseling and confirmatory genetic testing services are increasingly available in India through hospital-based clinical genetics departments and accredited diagnostic laboratories in major cities, and this access is expanding, though it remains more concentrated in urban centers than in smaller towns. When choosing where to seek follow-up, it is reasonable to ask directly whether a laboratory is accredited for clinical diagnostic use, and whether genetic counseling is available as part of the service, since the interpretation of a result matters as much as the laboratory work itself. Finally, if you are considering direct-to-consumer testing in the future rather than responding to a past result, the same principle applies in reverse: for any question tied to a specific worry, a strong family history, or a reproductive decision, starting with a genetic counselor rather than a consumer kit will generally get you a more complete and more trustworthy answer the first time.
Several risks are worth thinking through before purchasing a kit, separate from the accuracy concerns already described.
• Emotional impact without support. A result suggesting increased risk for a serious condition, or an unexpected finding such as a previously unknown relative or a surprise about family relationships, can arrive with no genetic counselor available to help a person process it, unlike a clinical test where pre-test counseling sets expectations in advance.
• False reassurance. A reassuring result can be just as harmful as a frightening one if it leads a person to skip a screening test or a genetic counseling referral that their family history would otherwise call for. A negative direct-to-consumer result for a handful of variants does not mean a person’s family history of a condition should be disregarded.
• Data privacy and long-term data use. A saliva sample and the DNA data generated from it are highly personal and permanent; they cannot be changed the way a password can. Consumers should read a company’s consent terms carefully to understand whether their data may be used for research, shared with pharmaceutical or insurance partners, or retained indefinitely, and what happens to that data if the company is acquired, changes ownership, or goes out of business. Recent, widely reported events involving a major direct-to-consumer testing company entering bankruptcy proceedings, with millions of customers’ genetic profiles among its assets, illustrate that this is not a hypothetical concern.
• No regulatory oversight equivalent to clinical laboratories in most cases. In India, there is currently no dedicated law specifically governing direct-to-consumer genetic testing. Existing frameworks, such as the Clinical Establishments Act and Medical Device Rules, apply only partially, and many products marketed online as “wellness” or “lifestyle” genetic tests fall outside meaningful oversight entirely. The Indian Academy of Medical Genetics has noted that quality assurance standards equivalent to those required of accredited clinical genetic testing laboratories do not exist for most of these products.
• Testing of children. Direct-to-consumer kits are sometimes purchased for children out of curiosity or concern, but professional guidelines generally advise against predictive or carrier testing of minors for adult-onset conditions outside a clinical setting, since this removes the child’s own future ability to decide whether they want that information, and a young person cannot meaningfully participate in informed consent for this kind of finding.None of this means direct-to-consumer testing is inherently harmful for every use, particularly for lower-stakes purposes such as ancestry. It does mean that going in with clear expectations, and treating any medically significant finding as a starting point rather than an endpoint, protects against most of the realistic downsides.
It helps to think of direct-to-consumer products as sitting on a spectrum, from reasonably reliable for their stated purpose to poorly supported by evidence.
• Ancestry and geographic origin. These estimates use large reference databases of population genetic variation and are generally reasonable for their intended purpose, though the precision of a breakdown, especially for South Asian sub-regions, is limited by how well those specific populations are represented in the company’s reference data.
• A small number of well-studied, high-impact variants. A handful of direct-to-consumer products, most notably certain authorized versions of major United States-based kits, report on specific, thoroughly validated disease-linked changes, such as three particular BRCA1 and BRCA2 variants common in one specific ancestral population, or a small set of variants linked to certain other adult-onset conditions. Where these exist, they can be a reasonable first flag, but a positive result still requires confirmation through accredited clinical testing before any medical decision is made, and a negative result covers only those specific variants, not the gene as a whole.
• Polygenic risk scores for common conditions. These combine the small individual effects of many genetic variants to estimate a relative risk for conditions such as heart disease, type 2 diabetes, or certain cancers. They are an active area of research but are not currently considered reliable enough, especially outside the population groups they were built on, to guide individual medical decisions on their own.
• Carrier status for recessive conditions. Some kits screen for carrier status in a limited panel of conditions. Unlike a clinical carrier screening panel chosen with a genetic counselor to match a person’s ethnic background, family history, and reproductive plans, a direct-to-consumer panel is fixed and may miss conditions that are actually most relevant to a particular family.
• Wellness, nutrition, fitness, and supplement recommendations. This category has the weakest scientific support of all direct-to-consumer offerings. Professional genetics organizations, including the Indian Academy of Medical Genetics, have specifically cautioned that clinical utility for these products has not been established, and they should not be used to guide medical, dietary, or supplement decisions.What direct-to-consumer testing cannot do, regardless of category, is replace a structured clinical evaluation for a person or family with a specific medical concern, such as a strong family history of a particular cancer, a child with unexplained developmental delay, or a couple planning a pregnancy with a known genetic condition in the family. Those situations call for testing chosen and interpreted by a genetics professional, using a laboratory equipped to look at the entire relevant gene, not a fixed consumer panel.
The honest answer is that accuracy varies enormously depending on what is being tested and how the company built its product, and this is one of the most consistent concerns raised by professional genetics organizations. Most direct-to-consumer kits use a technology called genotyping, which checks a large number of specific, pre-selected positions in the DNA rather than reading every letter of a gene from end to end the way a full clinical sequencing test does. Genotyping is a reasonable tool for ancestry estimates and for looking at well-established, common variants, but it is far more prone to a specific kind of error, a false positive, when it is used to flag rarer, disease-causing changes in genes such as those linked to hereditary cancer.
This is not a theoretical concern. A widely cited study by a clinical genetics laboratory took forty-nine samples where consumers had used third-party services to reinterpret their raw direct-to-consumer data and had received a report describing a variant of concern in a disease-related gene. When those same samples were retested using accredited, clinical-grade sequencing, forty in every hundred of the flagged variants turned out to be false positives, meaning the person did not actually carry that genetic change at all. Some people had already begun planning preventive surgery or additional screening based on results that were simply wrong. The pattern was strongest for raw genotyping data run through unregulated third-party interpretation tools rather than a company’s own core report, but the underlying lesson applies broadly: a result generated outside a clinical laboratory, without the quality checks that accredited diagnostic laboratories are required to meet, should be treated as a starting point for a conversation with a qualified professional, never as a final answer.
There is a separate and equally important limitation even when a result is technically correct: what it means for a person’s actual health. A polygenic risk estimate for a common condition combines many genetic variants of small individual effect, and how well these scores predict risk depends heavily on which population was used to build the underlying research, meaning a score built mostly from data on one ancestry group can be considerably less accurate for a person from a different background, including most people from India. A negative result on a direct-to-consumer test, such as one that only checks three specific breast cancer gene changes out of many hundreds, tells a person almost nothing about whether they carry a different, equally important change in the same gene, and should never be read as clearing someone of hereditary cancer risk if their family history otherwise suggests concern.
Direct-to-consumer genetic testing refers to any DNA test that a person can buy and use without a doctor or genetic counselor ordering it first. A kit is purchased online or over the counter, a saliva or cheek-swab sample is collected at home and mailed to a laboratory, and a report is sent back directly to the person, usually through a website or an application. This is fundamentally different from clinical genetic testing, where a doctor or genetic counselor first evaluates a person’s personal and family medical history, chooses a test suited to a specific medical question, and then reviews the result together with the person afterward.
Direct-to-consumer tests are marketed for several different purposes, and it matters a great deal which one a given product is designed for. Some report on ancestry and geographic origin. Some estimate risk for common, multi-factor conditions such as heart disease or type 2 diabetes based on many genetic variants combined, called polygenic risk. A smaller number look for specific, well-studied disease-causing changes, such as three particular changes in the BRCA1 and BRCA2 genes linked to breast and ovarian cancer risk, or genetic changes linked to conditions such as Parkinson disease. Others are marketed as “wellness” or nutrigenomic products, claiming to guide diet, fitness, or supplement choices based on genetic variants whose everyday relevance is often not well established. A single company’s kit may combine several of these categories in one report, and the quality of evidence behind each category can be very different even within the same kit.
The most important distinction for a patient or family member to hold onto is this: a direct-to-consumer test is not a substitute for a clinical genetic evaluation, even when it examines some of the same genes. It is typically not accompanied by a structured discussion of family history beforehand, and the laboratory generating the report is often not the same one that would be used for a diagnostic evaluation ordered by a physician. Professional bodies including the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors have both stated that when a result raises a genuine medical question, whether reassuring or concerning, it should be discussed with a doctor or genetic counselor rather than acted upon on its own, and the sections below explain why.
